Axsome Therapeutics, Inc. (AXSM)
179.25
-2.82
(-1.55%)
USD |
NASDAQ |
Oct 02, 16:00
179.15
-0.10
(-0.06%)
Pre-Market: 20:00
Axsome Therapeutics Enterprise Value : 9.280B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 9.280B |
| October 01, 2026 | 9.427B |
| September 30, 2026 | 9.548B |
| September 29, 2026 | 9.640B |
| September 28, 2026 | 10.05B |
| September 25, 2026 | 10.11B |
| September 24, 2026 | 10.16B |
| September 23, 2026 | 10.02B |
| September 22, 2026 | 10.53B |
| September 21, 2026 | 10.65B |
| September 18, 2026 | 10.77B |
| September 17, 2026 | 11.11B |
| September 16, 2026 | 10.99B |
| September 15, 2026 | 10.58B |
| September 14, 2026 | 11.23B |
| September 11, 2026 | 11.45B |
| September 10, 2026 | 10.95B |
| September 09, 2026 | 10.92B |
| September 08, 2026 | 10.77B |
| September 04, 2026 | 10.71B |
| September 03, 2026 | 10.80B |
| September 02, 2026 | 10.88B |
| September 01, 2026 | 10.51B |
| August 31, 2026 | 10.29B |
| August 28, 2026 | 10.31B |
| Date | Value |
|---|---|
| August 27, 2026 | 10.69B |
| August 26, 2026 | 10.74B |
| August 25, 2026 | 10.65B |
| August 24, 2026 | 10.65B |
| August 21, 2026 | 10.77B |
| August 20, 2026 | 10.78B |
| August 19, 2026 | 11.32B |
| August 18, 2026 | 11.19B |
| August 17, 2026 | 11.22B |
| August 14, 2026 | 11.08B |
| August 13, 2026 | 11.08B |
| August 12, 2026 | 11.13B |
| August 11, 2026 | 11.19B |
| August 10, 2026 | 11.46B |
| August 07, 2026 | 11.03B |
| August 06, 2026 | 10.89B |
| August 05, 2026 | 11.04B |
| August 04, 2026 | 11.00B |
| August 03, 2026 | 10.94B |
| July 31, 2026 | 11.31B |
| July 30, 2026 | 12.18B |
| July 29, 2026 | 11.80B |
| July 28, 2026 | 12.15B |
| July 27, 2026 | 12.37B |
| July 24, 2026 | 12.51B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.122T |
| Liquidia Corp. | 2.451B |
| Filana Therapeutics, Inc. | -37.71M |
| CorMedix, Inc. | 446.23M |
| Eloxx Pharmaceuticals, Inc. | 0.6386M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -51.31M |
| Revenue (Quarterly) | 218.38M |
| Total Expenses (Quarterly) | 269.69M |
| EPS Diluted (Quarterly) | -0.9906 |
| Gross Profit Margin (Quarterly) | 92.47% |
| Profit Margin (Quarterly) | -23.50% |
| Earnings Yield | -2.10% |
| Normalized Earnings Yield | -2.071 |